期刊
HEALTH AFFAIRS
卷 39, 期 9, 页码 1546-1556出版社
PROJECT HOPE
DOI: 10.1377/hlthaff.2020.00284
关键词
-
资金
- Pharmaceutical Research and Manufacturers of America
- Agency for Healthcare Research and Quality [T32-HS000055]
- Arnold Ventures
- Agency for Healthcare Research and Quality
- Centers for Medicare and Medicaid Services
- National Institutes of Health
- Blue Cross Blue Shield Association
- Health Care Service Corporation
- Ballad Health
- Peterson Center on HealthCare
- Robert Wood Johnson Foundation
- Commonwealth Fund
- Gary and Mary West Health Policy Center
- National Pharmaceutical Council
- Patient-Centered Outcomes Research Institute
- State of Michigan
Life expectancy in the US increased 3.3 years between 1990 and 2015, but the drivers of this increase are not well understood. We used vital statistics data and cause-deletion analysis to identify the conditions most responsible for changing life expectancy and quantified how public health, pharmaceuticals, other (nonpharmaceutical) medical care, and other/unknown factors contributed to the improvement. We found that twelve conditions most responsible for changing life expectancy explained 2.9 years of net improvement (85 percent of the total). Ischemic heart disease was the largest positive contributor to life expectancy, and accidental poisoning or drug overdose was the largest negative contributor. Forty-four percent of improved life expectancy was attributable to public health, 35 percent was attributable to pharmaceuticals, 13 percent was attributable to other medical care, and -7 percent was attributable to other/unknown factors. Our findings emphasize the crucial role of public health advances, as well as pharmaceutical innovation, in explaining improving life expectancy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据